16th Dec 2021 21:29
BATM Advanced Communications Ltd - Israel-based networking technology and medical lab systems - Begins first sales of RAPIDgen SARS-CoV-2 antigen test, in Russia, which is the first test to be approved by Russian health authorities.
First shipping order is worth EUR250,000, which is scheduled to be completed in December, and expects to receive greater orders of a greater value in 2022.
"We are delighted to have received further validation of the high quality of our rapid test when evaluated by teams of experts and compared with PCR tests, which are regarded as the 'gold standard'. We believe our test is the most accurate and easy-to-use test for at-home use in Russia, which represents a substantial market opportunity," says Chief Executive Officer Zvi Marom.
Current stock price: 77.33 pence, up 3.1% on Thursday
Year-to-date change: down 17%
By Dayo Laniyan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Batm Advanced